&nbsp;

IMPACT_Newsletter_Second_Edition

Nov 2019

Document

IMPACT_Newsletter_Third_Edition

Nov 2019

Document

IMPACT_Newsletter_Fourth_Edition

Nov 2019

Document

IMPACT_Newsletter_Fifth_Edition

Nov 2019

Regimen

ATEZ(MNT)

Cancer Type:

Lung,

Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer

New Drug Funding Program

Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer

Drugs Used:

atezolizumab,

atezolizumab (subcut)

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

ATEZBEVA(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

atezolizumab (Unfunded),

bevacizumab (Unfunded)

Quick Link(s):

Regimen Monograph

May 2025

Regimen

AC-PACL(W)+PERT+TRAS

Cancer Type:

Breast

Intent: Curative, Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

DOXOrubicin,

cyclophosphamide,

PACLitaxel,

PERTuzumab (Unfunded),

trastuzumab

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

AC-PACL(DD)+PERT+TRAS

Cancer Type:

Breast

Intent: Curative, Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

DOXOrubicin,

cyclophosphamide,

PACLitaxel,

PERTuzumab (Unfunded),

trastuzumab

Quick Link(s):

Regimen Monograph

Sep 2022

Statistical Reports

About This Report

Statistical Reports

Analysis

Regimen

AXIT+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

aXitinib,

pembrolizumab